Metal Binder Jetting
Automotive Polymers

ROKIT Healthcare’s bioprinting-based diabetic foot treatment kit registered as a U.S. FDA medical device

Share this Article

ROKIT Healthcare has completed registration of its Dr. INVIVO-based diabetic foot treatment with the U.S. FDA and has successfully completed clinical studies in the U.S.

Since 2019, the company has conducted clinical studies in India, Korea and Turkey, and based on the most recent study results in the U.S., the treatment has shown promising results in all of the study patients with no side effects.

The company reported that the study subjects were patients of chronic diabetic foot ulcer with an average of 64.4 years of age, 15 years of diabetes duration, and obesity in 90% of the patients.

The principal investigator behind the study is Dr. David G. Armstrong, PhD, DPM, who is Professor of Clinical Surgery at University of Southern California and has produced more than 510 peer-reviewed research papers in scholarly medical journals and 90 book chapters with expertise in the treatment and clinical care of the diabetic foot. Dr. Armstrong is past Chair of Scientific Sessions for the American Diabetes Association’s Foot Care Council and the founder and co-chair of the International Diabetic Foot Conference, the largest annual international symposium on the diabetic foot in the world.

“There is no existing method that resolves chronic diabetic foot ulcers by way of true regenerative medicine, especially for those ulcers that failed to close for many months,” said an official of ROKIT Healthcare. “We have seen our bioprinting-based diabetic foot ulcer treatment offer hope for patients who recovered and got back on their feet within just a few weeks after one procedure, making daily life possible again.

“The clinical study results have demonstrated that ROKIT Healthcare’s diabetic foot ulcer treatment kit can effectively regenerate skin of diabetic foot affected areas regardless of various variables such as race, age, and underlying disease. I can take one more step,” he said.

ROKIT Healthcare’s diabetic foot ulcer treatment, which consists of the printer Dr. INVIVO DFU and patient-specific autologous solution extraction kits, uses 3D scanning and AI-based interpretation of patient wounds to create customized skin regeneration patches.

“Given the FDA medical device registration and several successful global studies yielding promising results, we are proud to be leading a meaningful work of saving human lives with cutting-edge regenerative medicine technologies,” said Seok-Hwan You, CEO of ROKIT Healthcare. “I look forward to contributing to the advancement of chronic ulcer treatment methods and significantly improving the quality of life for patients.”

Share this Article


Recent News

3D Printing News Unpeeled, Live with Joris Peels – Tuesday 9th of August

UCLA Materials Scientists Awarded Grant for 3D Printed Batteries



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

Featured

3D Systems Buys High-Speed 3D Printing Firm dp polar

The 3D printing mergers and acquisitions continue apace. On the heels of Markforged’s buyout of Digital Metal and Nano Dimension’s 12 percent purchase of Stratasys, 3D Systems (NYSE: DDD) has...

New Player in Space: X-Bow’s Test Rocket Reaches Orbit with 3D Printed Motors

Just four months after coming out of stealth mode, space technology company X-Bow Launch Systems successfully launched its first rocket in a test carried out in partnership with the Department...

Sakuu Opens Battery 3D Printing Facility in Silicon Valley

Silicon Valley startup Sakuu is using some of the funds from its total $62 million raised to open a new facility for its battery 3D printing platform. The multi-million-dollar site...

US DoE Awards $3M to Fortify and polySpectra for 3D Printed Tooling

The US Department of Energy (DOE) announced 30 projects that have been selected to receive a total of $57.9 million in grants from the Advanced Manufacturing Office (AMO). Among the...